GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03139604 |
Recruitment Status :
Completed
First Posted : May 4, 2017
Results First Posted : May 15, 2020
Last Update Posted : August 11, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Graft-versus-host Disease (GVHD) | Drug: Itacitinib Drug: Placebo Drug: Prednisone Drug: Methylprednisolone | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 439 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Masking Description: | Double Blind |
Primary Purpose: | Treatment |
Official Title: | GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease |
Actual Study Start Date : | July 19, 2017 |
Actual Primary Completion Date : | May 2, 2019 |
Actual Study Completion Date : | July 13, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Itacitinib
Itacitinib plus corticosteroids
|
Drug: Itacitinib
Itacitinib at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
Other Name: INCB039110 Drug: Prednisone Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
Other Names:
Drug: Methylprednisolone Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.
Other Names:
|
Placebo Comparator: Placebo
Matching placebo plus corticosteroids
|
Drug: Placebo
Matching placebo tablets administered orally once daily (QD) plus corticosteroids. Drug: Prednisone Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
Other Names:
Drug: Methylprednisolone Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.
Other Names:
|
- Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response Index [ Time Frame: Day 28 ]Defined as the percentage of participants demonstrating a complete response (CR), very good partial response (VGPR), or partial response (PR).
- Nonrelapse Mortality [ Time Frame: Month 6,9,12 and 24 ]Defined as the percentage of participants who died due to causes other than malignancy relapse.
- Duration of Response [ Time Frame: Baseline through 30-35 days after end of treatment, total particpation expected to average 24 months ]Defined as the interval from first response until GVHD progression or death.
- Cmax of Itacitinib When Administered in Combination With Corticosteroids [ Time Frame: Protocol-defined timepoints up to Day 28 ]Defined as maximum observed plasma concentration.
- Cmin of Itacitinib When Administered in Combination With Corticosteroids [ Time Frame: Protocol-defined timepoints up to Day 28 ]Defined as minimum observed plasma concentration.
- Tmax of Itacitinib When Administered in Combination With Corticosteroids [ Time Frame: Protocol-defined timepoints up to Day 28 ]Defined as time to maximum plasma concentration.
- AUC of Itacitinib When Administered in Combination With Corticosteroids [ Time Frame: Protocol-defined timepoints up to Day 28 ]Defined as area under the concentration-time curve.
- CL/F of Itacitinib When Administered in Combination With Corticosteroids [ Time Frame: Protocol-defined timepoints up to Day 28 ]Defined as oral dose clearance.
- Time to Response [ Time Frame: End of Study, total particpation expected to average 24 months ]Defined as the interval from treatment initiation to first response
- Relapse Rate of Malignant and Nonmalignant Hematologic Disease [ Time Frame: Randomization through end of Study, study duration expected to average 24 months ]Defined as the proportion of subjects whose underlying hematologic disease relapses
- Malignancy Relapse-related Mortality Rate [ Time Frame: Randomization through end of Study, study duration expected to average 24 months ]Defined as the proportion of subjects whose malignancy relapses and has a fatal outcome.
- Failure-free Survival [ Time Frame: 6 months from randomization ]Defined as the proportion of subjects who are still alive, have not relapsed, have not required additional therapy for aGVHD, and have not demonstrated signs or symptoms of chronic graft-versus-host disease (cGVHD)
- Overall Survival (OS) [ Time Frame: End of Study up to approximately 24 months ]Defined as the interval from study enrollment to death due to any cause.
- Number of Treatment-emergent Adverse Events With INCB39110 [ Time Frame: 30-35 days after end of treatment, approximately 24 months ]Adverse events reported for the first time or worsening of a pre-existing event after the first dose of study treatment
- Incidence Rate of Secondary Graft Failure [ Time Frame: Randomization through end of Study, study duration expected to average 24 months ]Defined as > 95% recipient cells any time after engraftment with no signs of relapse, OR retransplantation because of secondary neutropenia (< 0.5 × 109/L) and/or thrombocytopenia (< 20 × 109/L) within 2 months of transplantion
- Proportion of Subjects Who Discontinue Corticosteroids [ Time Frame: Days 28, 56, 100, and 180 ]Average and cumulative corticosteroid dose usage will be calculated and proportion of subjects discontinuing corticosteroids will be tabulated
- Proportion of Subjects Who Discontinue Immunosuppressive Medications [ Time Frame: Days 56 and 100 ]Summary statistics of subjects discontinuing immunosuppressive medications will be calculated
- Incidence Rate of aGVHD Flares [ Time Frame: up to day 100 ]
- Incidence Rate of cGVHD [ Time Frame: Days 180 and 365 ]
- Objective Response Rate [ Time Frame: Days 14, 56 and 100 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Has undergone 1 allo-HSCT from any donor (related or unrelated with any degree of HLA matching) and any donor source (bone marrow, peripheral blood stem cells, or cord blood) for a hematologic malignancy or disorder. Recipients of myeloablative and reduced-intensity conditioning regimens are eligible.
- Clinically suspected Grade II to IV aGVHD as per MAGIC criteria, occurring after allo-HSCT and any GVHD prophylaxis regimen.
- Evidence of myeloid engraftment. Use of growth factor supplementation is allowed.
- Serum creatinine ≤ 2.0 mg/dL or creatinine clearance ≥ 40 mL/min measured or calculated by Cockroft Gault equation.
- Willing to avoid pregnancy or fathering children.
- Able to give written informed consent and comply with all study visits and procedures.
- Able to swallow and retain oral medication.
Exclusion Criteria:
- Has received more than 1 allo-HSCT.
- Has received more than 2 days of systemic corticosteroids for aGVHD.
- Presence of GVHD overlap syndrome.
- Presence of an active uncontrolled infection.
- Known human immunodeficiency virus infection.
- Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment or at risk for HBV reactivation.
- Participants with evidence of relapsed primary disease, or participants who have been treated for relapse after the allo-HSCT was performed.
- Any corticosteroid therapy for indications other than GVHD at doses > 1 mg/kg per day methylprednisolone (or prednisone equivalent) within 7 days of randomization.
-
Severe organ dysfunction unrelated to underlying GVHD, including:
- Cholestatic disorders or unresolved veno-occlusive disease of the liver.
- Clinically significant or uncontrolled cardiac disease.
- Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.
- Currently breast feeding.
- Received JAK inhibitor therapy after allo-HSCT for any indication. Treatment with a JAK inhibitor before allo-HSCT is permitted.
- Treatment with any other investigational agent, device, or procedure within 21 days (or 5 half-lives, whichever is greater) of enrollment.
- Any medical complications or conditions that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
- Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03139604
Study Director: | Rodica Morariu-Zamfir, MD | Incyte Corporation |
Documents provided by Incyte Corporation:
Responsible Party: | Incyte Corporation |
ClinicalTrials.gov Identifier: | NCT03139604 |
Other Study ID Numbers: |
INCB 39110-301 |
First Posted: | May 4, 2017 Key Record Dates |
Results First Posted: | May 15, 2020 |
Last Update Posted: | August 11, 2021 |
Last Verified: | July 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Acute graft-versus-host disease Janus kinase (JAK) inhibitor itacitinib corticosteroids allogeneic hematopoietic stem cell transplant (allo-HSCT) |
Graft vs Host Disease Immune System Diseases Prednisone Methylprednisolone Methylprednisolone Acetate Methylprednisolone Hemisuccinate Prednisolone Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Anti-Inflammatory Agents Glucocorticoids |
Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents |